Search Results
Jun 06, 2026, 13:00 ET Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association's 2026 Scientific Sessions
waist-to-height ratio [WtHR], systolic and diastolic blood pressure [BP], triglycerides, non-HDL cholesterol, hsCRP) and liver health parameters including ALT, controlled attenuation parameter, Enhanced Liver Fibrosis, FibroScan-AST, liver stiffness measurement) versus placebo up to week 72, regardless of baseline
More news about: NOVO NORDISK INC.
Jun 04, 2026, 12:00 ET Ny undersøgelse fra Apica: Agentbaseret AI forventes at udløse en 9,5-dobling af telemetridata, hvilket vil efterlade de fleste virksomheder sårbare
samlet ejeromkostning, der er op til 40 % lavere end hos ældre observabilitetsplatforme. I modsætning til platformcentrerede løsninger, der indsamler alt uden skelnen og opkræver gebyrer ved hvert trin, behandler, beriger og styrer Apicas pipeline-baserede arkitektur telemetridataene, inden de indsamles
More news about: Apica
Jun 04, 2026, 11:55 ET Ny forskning fra Apica: Agentisk AI kan utløse en eksplosjon i telemetridata på opptil 9,5 ganger, noe som gjør de fleste bedrifter sårbare
krever, med opptil 40 prosent lavere totalkostnad enn eldre plattformer for observerbarhet. I motsetning til plattformsentriske løsninger som tar inn alt uten seleksjon og tar betaling for hvert trinn, behandler, beriker og styrer Apicas pipeline-første arkitektur telemetridata før kostbar plattforminntak,
More news about: Apica
Jun 04, 2026, 03:00 ET UGREEN blir med i 2026 Terra Wortmann Open som offisiell partner med "Power for Your Game»
kraftig multi-enhet lading. For ansatte eller medieteam som administrerer flere enheter, gir serien en alt-i-ett-løsning, med innebygde kabler, høykapasitetsutgang og multi-enhet lading, slik at alt fra telefoner til bærbare datamaskiner forblir klar gjennom hele turneringen.Styrke for hvert
More news about: UGREEN Limited
Jun 04, 2026, 03:00 ET UGREEN bliver officiel partner for Terra Wortmann Open 2026 med sloganet "Strøm til dit spil"
enheder. For medarbejdere eller medieteams, der administrerer flere enheder, tilbyder serien en alt-i-én-løsning med indbyggede kabler, høj udgangseffekt og opladning af flere enheder, hvilket sikrer, at alt fra mobiltelefoner til bærbare computere er klar til brug under hele turneringen.Styrke
More news about: UGREEN Limited
Jun 03, 2026, 15:33 ET EUROPÄISCHE KOMMISSION ERTEILT ZULASSUNG FÜR IMDYLLTRA® VON AMGEN FÜR DIE BEHANDLUNG VON KLEINZELLIGEM LUNGENKREBS IM FORTGESCHRITTENEN STADIUM
In der gepoolten Sicherheitspopulation traten auf der Grundlage von Labordaten bei 39 % der Patienten, die IMDELLTRA® erhielten, erhöhte ALT-Werte auf, darunter bei 2,5 % Werte des Grades 3 oder 4. Erhöhte AST-Werte traten bei 43 % der Patienten auf, darunter 3,2 % vom Grad 3 oder 4. Erhöhte
More news about: Amgen
Jun 03, 2026, 15:16 ET LA COMMISSION EUROPÉENNE APPROUVE IMDYLLTRA® D'AMGEN POUR LE TRAITEMENT DU CANCER DU POUMON À PETITES CELLULES DE STADE ÉTENDU
basée sur les données de laboratoire, une élévation de l'ALT est survenue chez 39 % des patients ayant reçu IMDELLTRA®, dont 2,5 % avec une ALT de grade 3 ou 4. Une élévation des ASAT a été observée chez 43 % des patients, dont 3,2 % de grade 3 ou 4. Une élévation de la bilirubine a également
More news about: Amgen
Jun 03, 2026, 14:25 ET EURÓPSKA KOMISIA SCHVÁLILA LIEK IMDYLLTRA® SPOLOČNOSTI AMGEN NA LIEČBU POKROČILÉHO ŠTÁDIA MALOBUNKOVÉHO KARCINÓMU PĽÚC
združenej bezpečnostnej populácii sa na základe laboratórnych údajov vyskytla zvýšená aktivita ALT u 39 % pacientov, ktorí dostávali liek IMDELLTRA®, z toho u 2,5 % išlo o zvýšenie aktivity ALT 3. alebo 4. stupňa. Zvýšená aktivita AST sa vyskytla u 43 % pacientov, z toho u 3,2 % išlo o 3.
More news about: Amgen
Jun 03, 2026, 13:35 ET EVROPSKÁ KOMISE SCHVÁLILA PŘÍPRAVEK IMDYLLTRA® OD SPOLEČNOSTI AMGEN K LÉČBĚ EXTENZIVNÍHO STADIA MALOBUNĚČNÉHO KARCINOMU PLIC
hepatotoxicitu. V celkovém sledování bezpečnosti u populace se na základě laboratorních údajů vyskytlo zvýšení ALT u 39 % pacientů léčených přípravkem IMDELLTRA®, včetně 2,5 % s ALT 3. nebo 4. stupně. Zvýšená hladina AST se vyskytla u 43 % pacientů, včetně 3,2 % s 3. nebo 4. stupněm. Ke zvýšení
More news about: Amgen
Jun 03, 2026, 12:10 ET VIOLIFE®, THE #1 DAIRY FREE CHEESE BRAND* TURNS CRAVINGS INTO CURRENCY WITH CRAVING CREDITS
Learn more at culinarycareers.org.*Violife® dairy free cream cheese: 41.2% Unit Share in such category. Nielsen, U.S. Unit Share of Alt Cheese, latest 26 weeks, week ending 05/18/2026.**Offer valid 5/26/26 - 6/26/26. Must purchase any dairy product in a single transaction.
More news about: Flora Food Group
Jun 03, 2026, 10:21 ET KOMISJA EUROPEJSA ZATWIERDZA PREPARAT IMDYLLTRA® FIRMY AMGEN DO LECZENIA DROBNOKOMÓRKOWEGO RAKA PŁUCA W POSTACI ROZSIANEJ
IMDELLTRA®.Hepatotoksyczność: IMDELLTRA® może powodować hepatotoksyczność. W zbiorczej populacji bezpieczeństwa, na podstawie danych laboratoryjnych, podwyższenie aktywności ALT wystąpiło u 39% pacjentów otrzymujących preparat IMDELLTRA®, w tym u 2,5% w stopniu 3 lub 4. Podwyższenie aktywności AST wystąpiło u 43% pacjentów, w
More news about: Amgen
Jun 03, 2026, 09:43 ET ЕВРОПЕЙСКАЯ КОМИССИЯ ОДОБРИЛА ПРЕПАРАТ AMGEN IMDYLLTRA® ДЛЯ ЛЕЧЕНИЯ МЕЛКОКЛЕТОЧНОГО РАКА ЛЕГКОГО НА ЗАПУЩЕННОЙ СТАДИИ
гепатотоксичность. В объединенной популяции безопасности, на основании лабораторных данных, повышенный уровень ALT наблюдался у 39% пациентов, получавших IMDELLTRA®, в том числе у 2,5% пациентов с ALT 3 или 4 степени. Повышенный уровень AST наблюдался у 43% пациентов, в том числе у 3,2% пациентов 3-й
More news about: Amgen
Jun 03, 2026, 09:27 ET LA CE APRUEBA IMDYLLTRA® DE AMGEN PARA EL CÁNCER DE PULMÓN DE CÉLULAS PEQUEÑAS EN ESTADIO AVANZADO
hepatotoxicidad. En la población de seguridad combinada, según los datos de laboratorio, se observó elevación de ALT en el 39 % de los pacientes que recibieron IMDELLTRA®, incluyendo un 2,5 % con ALT de grado 3 o 4. Se observó elevación de AST en el 43 % de los pacientes, incluyendo un 3,2 % con grado
More news about: Amgen
Jun 03, 2026, 09:00 ET AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026
elevation in alanine aminotransferase [ALT] or aspartate aminotransferase [AST] to >3 times the upper limit of normal, evaluate promptly and consider pausing treatment as clinically indicated. If AST or ALT is > 5 times the upper limit of normal (ULN), or ALT or AST > 3 times the ULN with total
More news about: Amgen
Jun 02, 2026, 09:30 ET Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting
AST increased (17; 1.6), pneumonia (16; 14), bruising (16; -), potassium decreased (13; 1.6), sodium decreased (13; -), lipase increased (12; 4.4), ALT increased (11; 1.6), potassium increased (11; 0.8), alkaline phosphatase increased (11; -). Grade 4 laboratory abnormalities in >5% of patients included
More news about: Eli Lilly and Company
Jun 01, 2026, 16:00 ET EUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
IMDELLTRA® can cause hepatotoxicity. In the pooled safety population, based on laboratory data, elevated ALT occurred in 39% of patients who received IMDELLTRA®, including 2.5% with Grade 3 or 4 ALT. Elevated AST occurred in 43% of patients, including 3.2% Grade 3 or 4. Elevated bilirubin also occurred
More news about: Amgen
Jun 01, 2026, 11:00 ET IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO
3/4 TRAEs included diarrhea (10.0%), syncope (7.1%) and hypotension (3.8.%) in the darovasertib combination arm compared to elevated liver enzymes (ALT, 7.0% / AST, 7.0%), diarrhea (6.0%), hepatitis (5.0%) and colitis (4.0%) in the ICT control arm.In April 2026, IDEAYA announced
More news about: IDEAYA Biosciences, Inc.
Jun 01, 2026, 07:00 ET Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies
medical management.HepatotoxicityLYMPHIR can cause hepatotoxicity. In the pooled safety population, elevated ALT occurred in 70% of patients, with Grade 3 ALT occurring in 22%; elevated AST occurred in 64% of patients, with Grade 3 AST elevation occurring in 9%. For Grade 3 events, median
More news about: Citius Oncology, Inc.
May 31, 2026, 08:29 ET RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
severity.HepatotoxicityLAZCLUZE® in combination with amivantamab can cause severe hepatotoxicity (including increased ALT and AST).RYBREVANT® with LAZCLUZE®In MARIPOSA, based on adverse reaction data,
More news about: Johnson & Johnson
May 31, 2026, 08:01 ET Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
(AST) occurred in 59% of patients, including Grade 3 or 4 events in 11% and increased alanine aminotransferase (ALT) occurred in 55% of patients, including Grade 3 or 4 events in 12%. Monitor ALT and AST prior to initiating Retevmo, every 2 weeks during the first 3 months, then monthly thereafter and as
More news about: Eli Lilly and Company
May 29, 2026, 14:00 ET RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
severityHepatotoxicityLAZCLUZE® in combination with amivantamab can cause severe hepatotoxicity (including increased ALT and AST).RYBREVANT® with LAZCLUZE®In MARIPOSA, based on adverse reaction data,
More news about: Johnson & Johnson
May 29, 2026, 08:18 ET New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
N=448) elevated aspartate aminotransferase (AST) occurred in 47% of patients, with Grade 3 or 4 elevations in 2.9%. Elevated alanine aminotransferase (ALT) occurred in 48% of patients, with Grade 3 or 4 elevations in 3.8%. Elevated total bilirubin occurred in 10% of patients with Grade 3 or 4 elevations
More news about: Johnson & Johnson
May 29, 2026, 08:00 ET AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
decreased (78%), glucose increased (74%), lymphocytes decreased (56%), platelets decreased (43%), hemoglobin decreased (35%), calcium decreased (30%), ALT increased (26%), urate increased (25%), LDH increased (24%), potassium increased (22%), AST increased (22%), ALP increased (20%), glucose decreased (20%),
More news about: AbbVie
May 29, 2026, 08:00 ET AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
decreased (78%), glucose increased (74%), lymphocytes decreased (56%), platelets decreased (43%), hemoglobin decreased (35%), calcium decreased (30%), ALT increased (26%), urate increased (25%), LDH increased (24%), potassium increased (22%), AST increased (22%), ALP increased (20%), glucose decreased (20%),
More news about: AbbVie
May 28, 2026, 14:04 ET Enlit Africa 2026: Huawei, Sahra Altı Afrika için Akıllı Trafo Merkezi Çözümünü Piyasaya Sürdü
content:https://www.prnewswire.com/news-releases/enlit-africa-2026-huawei-sahra-alt-afrika-icin-akll-trafo-merkezi-cozumunu-piyasaya-surdu-302784869.html
More news about: Huawei